Pharmacologic Treatment of Acute Major Depression and Dysthymia: Clinical Guideline, Part 1
Authors: Vincenza Snow, Steven Lascher, Christel Mottur-Pilson
Journal: Annals of Internal Medicine (2000)

Position Papers2 May 2000Pharmacologic Treatment of Acute Major Depression and Dysthymia: Clinical Guideline, Part 1Vincenza Snow, MD, Steven Lascher, DVM, MPH, and Christel Mottur-Pilson, PhD, for the American College of Physicians-American Society of Internal Medicine*.Vincenza Snow, MD, Steven Lascher, DVM, MPH, and Christel Mottur-Pilson, PhD, for the American College of Physicians-American Society of Internal Medicine*.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-132-9-200005020-00010 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail The numbers in square brackets are cross-references to the numbered sections in the accompanying background paper, "A Systematic Review of Newer Pharmacotherapies for Depression in Adults: Evidence Report Summary," which is part 2 of this guideline (see pages743-756).Major depression and dysthymia are two of the most common and debilitating illnesses. The World Health Organization estimates that worldwide, major depression is the fourth leading cause of loss of disability-adjusted life-years. Major depression is a clinical syndrome lasting at least 2 weeks, during which the patient experiences either depressed mood or anhedonia plus at least five of the following symptoms: depressed ...References1. Mulrow CD, Williams JW Jr, Trivedi M, Chiquette E, Aquilar C, Cornell JE. Treatment of Depression: Newer Pharmacotherapies. Evidence Report/Technology Assessment No. 7. Rockville, MD: Agency for Health Care Policy and Research; February 1999. AHCPR Publication No. 99-E014. www.ahcpr.gov/clinic/depresumm.htm. Google Scholar2. Glass RM. Treating depression as a recurrent or chronic disease [Editorial]. JAMA. 1999;281:83-4. CrossrefMedlineGoogle Scholar3. Depression Guideline Panel. Depression in Primary Care. Volume 2. Treatment of Major Depression. Clinical Practice Guideline No. 5. Rockville, MD: U.S. Department of Health and Human Services; 1993. AHCPR Publication No. 93-0551. Google Scholar4. Physicians' Desk Reference. Montvale, NJ: Medical Economics; 1998. Google Scholar5. Simon GE, VonKorff M, Heiligenstein JH, Revicki DA, Grothaus L, Katon W, et al . Initial antidepressant choice in primary care. Effectiveness and cost of fluoxetine vs tricyclic antidepressants. JAMA. 1996;275:1897-902. CrossrefMedlineGoogle Scholar6. Red Book Update. Montvale, NJ: Medical Economics; 1998. Google Scholar7. Reynolds CF, Frank E, Perel JM, Imber SD, Cornes C, Miller MD, et al . Nortriptyline and interpersonal psychotherapy as maintenance therapies for recurrent major depression: a randomized, controlled trial in patients older than 59 years. JAMA. 1999;281:39-45. CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: For definitions of terms, see Glossary.For other ACP-ASIM Clinical Practice Guidelines, see www.acponline.org/sci-policy/guidelines.This paper, written by Vincenza Snow, MD, Steven Lascher, DVM, MPH, and Christel Mottur-Pilson, PhD, was developed by the Clinical Efficacy Assessment Subcommittee: David C. Dale, MD, Chair; William E. Golden, MD; Robert D. McCartney, MD; Keith W. Michl, MD; Stephen G. Pauker, MD; Sean R. Tunis, MD; Kevin B. Weiss, MD; Preston L. Winters, MD; and John J. Whyte, MD. Approved by the Board of Regents on 17 July 1999.Disclaimer: The authors of this article are responsible for its content, including any clinical or treatment recommendations. No statement in this article should be construed as an official position of the Agency for Healthcare Research and Quality or the U.S. Department of Health and Human Services.Corresponding Author: Customer Service, American College of Physicians-American Society of Internal Medicine, 190 N. Independence Mall West, Philadelphia, PA 19106.Current Author Addresses: Drs. Snow, Lascher, and Mottur-Pilson: Scientific Policy Department, Education Division, American College of Physicians-American Society of Internal Medicine, 190 N. Independence Mall West, Philadelphia, PA 19106. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByPrevalence, median time, and associated factors with the likelihood of initial antidepressant change: a cross-sectional study in QatarThe Quality of Life, Depression Levels and Coping Styles of Patients on Kidney Transplant Waiting ListPharmacological, psychological, and non-invasive brain stimulation interventions for treating depression after strokePrevalence and associated factors of depressive symptoms among chronic kidney disease patients in China: Results from the Chinese Cohort Study of Chronic Kidney Disease (C-STRIDE)Diagnosis and treatment of post-stroke depression in China: a cross-sectional survey of 350 senior clinicians in neurology, geriatrics, and rehabilitation departmentsEfficacy and tolerability of pharmacotherapy for post-stroke depression: a network meta-analysisApproach to Depression in Patients with Brain Diseases: Stroke, Parkinson's Disease, and DementiaInterventions for management of post-stroke depression: A Bayesian network meta-analysis of 23 randomized controlled trialsQuality indicators for care of depression in primary care settings: a systematic reviewA Comparison of Nurse Practitioners, Physician Assistants, and Primary Care Physicians' Patterns of Practice and Quality of Care in Health CentersThe Effectiveness or Efficacy of Modified Nursing Interventions Classification (NIC) in Reducing the Severity of Depression among Patients with Myocardial InfarctionEfficacy and feasibility of antidepressant treatment in patients with post-stroke depressionAssociations of 5HTTLPR polymorphism with major depressive disorder and alcohol dependence: A systematic review and meta-analysisPoststroke Depression: Mechanisms and ManagementRationale and design of the Chronic Kidney Disease Antidepressant Sertraline Trial (CAST)Prevalence of psychiatric disorders in patients with diabetes types 1 and 2Depression and sexual dysfunction in chronic kidney disease: a narrative review of the evidence in areas of significant unmet needProteinuria Is Associated with Quality of Life and Depression in Adults with Primary Glomerulopathy and Preserved Renal FunctionA practical approach to the treatment of depression in patients with chronic kidney disease and end-stage renal diseasePsychopharmakaCognition in the aging adultAnxiety and Depression in Maintenance Dialysis Patients: Preliminary Data of a Cross-sectional Study and Brief Literature ReviewAntidepressant Use and Cognitive Functioning in Older Medical Patients With Major or Minor DepressionEconomic Impact of Nonpersistence with Antidepressant Treatment in the Adult Population of Quebec: A Comparative Cost-Effectiveness ApproachSerum IL-6, albumin and comorbidities are closely correlated with symptoms of depression in patients on maintenance haemodialysisPsychopharmakaDietary fats in relation to depressive symptoms by cardiovascular disease risk factors status of elderly people living in Mediterranean islandsPsychopharmakaHerbal ToxicityEpidemiology, Diagnosis, and Management of Depression in Patients With CKDValidation of Depression Screening Scales in Patients With CKDMood disorders in patients with chronic kidney disease. Diagnosis, screening and treatment of depressionAlgorithms: STAR*D, Positives, Negatives, and Implications for Clinical PracticeThe Use of Selected Medicinal Herbs for Chemoprevention and Treatment of Cancer, Parkinson's Disease, Heart Disease, and DepressionSerotonin Syndrome Risks When Combining SSRI/SNRI Drugs and Triptans: is the FDA's Alert Warranted?Interventions for treating depression after strokeDeath or hospitalization of patients on chronic hemodialysis is associated with a physician-based diagnosis of depressionThe cost-effectiveness of sertraline in the treatment of depressionPotentially inappropriate management of depressive symptoms among Ontario home care clientsQSAR Study on Dual 5-HT1Aand 5-HT1BAntagonists: An Insight into the Structural Requirement for Antidepressant ActivityMapping computerized clinical guidelines to electronic medical records: Knowledge-data ontological mapper (KDOM)PsychopharmakaDepression in Patients With Chronic Renal Disease: Where Are We Going?Psychosocial Aspects of Chronic Disease: ESRD as a Paradigmatic IllnessPrimary Care Visit Length, Quality, and Satisfaction for Standardized Patients with DepressionScreening, Diagnosis, and Treatment of Depression in Patients with End-Stage Renal DiseaseDepression in End-Stage Renal Disease Patients: A Critical ReviewQuality Indicators for the Care of Depression in Vulnerable EldersBlack cohosh with or without St. John's wort for symptom-specific climacteric treatment—Results of a large-scale, controlled, observational studyPerimenopause and depression: strength of association, causal mechanisms and treatment recommendationsCare Management for Poststroke DepressionCurrent practices in depression careDepression in end-stage renal disease hemodialysis patientsThe predictive value of self-report scales compared with physician diagnosis of depression in hemodialysis patientsAntidepressant medication use in palliative careSynthesis and SAR of highly potent dual 5-HT1A and 5-HT1B antagonists as potential antidepressant drugsIncorporating pharmacoeconomic and health outcomes into randomized clinical trialsDuloxetine: A balanced and selective norepinephrine- and serotonin-reuptake inhibitorChallenges in Systematic Reviews That Evaluate Drug Efficacy or EffectivenessP. Lina Santaguida, PhD, Mark Helfand, MD, MPH, and Parminder Raina, PhDDepression and anxietyManagement of Depression After StrokePSYCHOSOCIAL FACTORS IN PATIENTS WITH CHRONIC KIDNEY DISEASE: Depression in End-Stage Renal Disease Patients Treated With Hemodialysis: Tools, Correlates, Outcomes, and NeedsInterventions for treating depression after strokeUse of Antidepressant MedicationsA Double-Blind, Randomized, 26-Week Study Comparing the Cognitive and Psychomotor Effects and Efficacy of 75 mg (37.5 mg b.i.d.) Venlafaxine and 75 mg (25 mg Mane, 50 mg Nocte) Dothiepin in Elderly Patients with Moderate Major Depression Being Treated in General PracticeHeadache Treatment Before and After the Consultation of a Specialized Centre: A Pharmacoepidemiology StudyPublic Awareness about Depression: The Effectiveness of a Patient GuidelineImproving Recognition of Depression in Primary Care: A Study of Evidence-Based Quality ImprovementPsychopharmakaEinsparpotentialePsychopharmakaMajor depressive disorder in the general hospital: adaptation of clinical practice guidelinesDiagnostic Evaluation of Elderly Patients with Mild Memory ProblemsJason H.T. Karlawish, MD and Christopher M. Clark, MDRelationships of Alcohol Use, Stress, Avoidance Coping, and other Factors with Mental Health in a Highly Educated WorkforceAntidepression PharmacologySelección de medicamentos en el anciano (II): recomendaciones específicas en las enfermedades más relevantes"Does This Mean I'm Crazy?" Hidden Worries of Treatment-Naive PatientsAntidepressant Treatment Patterns and Success Rates in a Managed Care OrganizationHerbal RemediesCardiovascular effects of psychotropic drugsRational treatment choices for non-major depressions in primary careNew St. John's Wort Study Raises More Questions Than AnswersMajor depressive disorderPsychosocial factors in dialysis patientsThe Cost–Utility of Screening for Depression in Primary CareMarcia Valenstein, MD, MS, Sandeep Vijan, MD, MS, John E. Zeber, MHA, Kathryn Boehm, MD, MS, and Amna Buttar, MD, MSMethods of Cognitive Analysis to Support the Design and Evaluation of Biomedical Systems: The Case of Clinical Practice GuidelinesEinsparpotentialePsychopharmakaGenerika und AnalogpräparateArzneimittelinteraktionen mit JohanniskrautextraktEstrogen Therapy in Perimenopausal Affective DisordersAntidepressiva-Übersicht für die klinische PraxisPsychopharmakaTherapie mit PsychopharmakaDepressionAnalogpräparatePsychopharmakaPsychopharmaka 2 May 2000Volume 132, Issue 9Page: 738-742KeywordsAntidepressantsClinical trialsDrug therapyDrugsDysthmiaElderlyReuptake inhibitorsSuicideTreatment guidelinesTricyclic antidepressants Issue Published: 2 May 2000 CopyrightCopyright © 2000 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...